Jeffrey McCurdy MD PhD

@P_DeepakIBDMD @HelmsleyTrust @WashUMedGastro @WashUDeptMed @satishev @EmoryPediatrics @CoulterBME @DrAilsaHart @philtozer1 @ibdseb @jalpa_devi @IBD_JohnD @AmerGastroAssn @AmCollegeGastro @CrohnsColitisFn @drvishal82 Representing for PFCD!!! Congrats my man.

Delighted to share that the @HelmsleyTrust has awarded a $3.2 million grant to the three of us: myself @WashUMedGastro @WashUDeptMed, Satish Viswanath, PhD @satishev, an associate professor in the Departments of Pediatrics & Biomedical Engineering @EmoryPediatrics @CoulterBME & David H. Ballard, MD @DavidBallardMD @WashUMedMIR. The project will validate: 👉Newly developed radiologic definitions for fistula improvement and response through the TOpCLASS fistula consortium. cghjournal.org/article/S1542-… 👉 Fully automated fistula segmentation neural network model on routine pelvic MRIs. spiedigitallibrary.org/conference-pro… 👉Further, using advanced computational approaches and artificial intelligence (deep learning) methods, the grant would allow the development of novel radiomics tools to measure fistula response that can be eventually deployed in clinical practice and trials in perianal Crohn’s disease drug development and surgical care pathways.

@waqqasafif @MatthieuAllez @MondayNightIBD @CanGastroAssn Come check out practice changing research in IBD. What is the best therapy for ICI colitis and does a low emulsifier diet work for CD? + lots of other exciting stuff. See QR code to join

Please join us for our post DDW 2025 IBD Update on Monday June 16th at 8 PM EST to review the top 5 presented IBD abstracts. Expert commentary by @MatthieuAllez @GI_JeffMD @MondayNightIBD @CanGastroAssn Register at us02web.zoom.us/webinar/regist…

Open to all HCPs interested in hearing about the latest, practice changing research in IBD from DDW2025

Anyone involved in taking care of patients with perianal Crohn’s disease or living with this condition, please help us with this international survey on priority setting for clinical research.

HCPs and individuals living with perianal Crohn’s disease please join us for the first international conference on perianal Crohn’s disease. Link to register. sayso.health/events/topclas…

@hany75516692 @waqqasafif @vipuljairath @MondayNightIBD Yes we will be talking about the COSTA trial on efficacy of appendectomy for UC.

Please join us tomorrow at 7 PM EST for our ECCO IBD update with @vipuljairath @GI_JeffMD Will be discussing the top 5 abstracts, including an abstract on the treatment of UC with appendectomy! See link below to register @MondayNightIBD

@IBDimmunology @MondayNightIBD @DCharabaty @EliLillyandCo @waqqasafif @BattatMD4IBD @JosephHabibi_MD @ibdgijami @nloganmd @DhereMdEmory @ibdseb @KajaliMishra @SumonaB_MD @AmerGastroAssn @AGA_Gastro @AmCollegeGastro @AGA_CGH @DrMohamadShehab @TBessissow The confidence intervals overlap for many of the pairwise comparisons in these NMA. Therefore, I wouldn’t agree with superiority for comparisons between the anti-IL23s.

@MondayNightIBD @DCharabaty @EliLillyandCo @waqqasafif @BattatMD4IBD @JosephHabibi_MD @ibdgijami @nloganmd @DhereMdEmory @ibdseb @GI_JeffMD @KajaliMishra @SumonaB_MD @AmerGastroAssn @AGA_Gastro @AmCollegeGastro 2/2: Endo remission NMA supporting the @AmerGastroAssn guidelines @AGA_CGH @DrMohamadShehab @TBessissow ✅Table 2 + Sup Table 8,9,12 - bottom row 🟠UPA > RIS > GUS - agree? cghjournal.org/article/S1542-…

📣Join us now for a convo led by @IBDimmunology @DCharabaty With 🆕MOAs in our 🧰 What’s next for #ulcerativecolitis after TNFi ? How do you ⚖️ efficacy/ safety/ comorbidities / age? 🗳️IBDPoll👇🏽 💬Share your thoughts Supported by educational grant @EliLillyandCo

@DCharabaty @IBDimmunology @Waseem_AhmedMD @MondayNightIBD @EliLillyandCo @waqqasafif @BattatMD4IBD @JosephHabibi_MD @ibdgijami @nloganmd @DhereMdEmory @ibdseb @KajaliMishra @SumonaB_MD @AmerGastroAssn @AGA_Gastro @DrPhil_Gu @IBDPharmD @IBDPharmacist This is where NMAs break down? Data from multiple disease types (CD and psoriasis) demonstrate superiority of IL23 blockade over IL12/23. Without an RCT in UC, I trust the consistency of direct comparison in multiple disease types over results from indirect comparisons.

@IBDimmunology @Waseem_AhmedMD @MondayNightIBD @EliLillyandCo @waqqasafif @BattatMD4IBD @JosephHabibi_MD @ibdgijami @nloganmd @DhereMdEmory @ibdseb @GI_JeffMD @KajaliMishra @SumonaB_MD @AmerGastroAssn @AGA_Gastro 🤔@IBDimmunology Per AGA: bioexposed UC: higher efficacy=JAKi (agree) & UST; intermediate efficacy=IL23p19; I recall UST efficacy not affected by prior bio-exposure, but is it more effective than p19 & as effective as JAK? “reverse” SEQUENCE? @DrPhil_Gu @IBDPharmD @IBDPharmacist

GI friends - please take a minute to fill out this survey on research priorities for PFCD.

@waqqasafif @ibdseb @TBessissow @novakkerri @DCharabaty @MondayNightIBD @EliLillyandCo @BattatMD4IBD @IBDimmunology @JosephHabibi_MD @BassiMehak @vipuljairath @laura_tee_mdgi @ptandonGI @RPanaccione @marshllj @JeanFredericCo1 @EdwardLoftus2 @SaraElOualiMD @MatthieuAllez @ChrisMa_YYC @NarulaNeeraj @IBD_Afzali @ibdgijami @nloganmd @DrPhil_Gu @ibdtweets @MRegueiroMD @PeyrinBiroulet @RestelliniS @bverstockt @SeverineVermei1 Agree WA. Exception being perianal CD and AS. We also found lower rates of luminal penetrating disease in patients treated with anti-tnf vs UST (@P_DeepakIBDMD). Therefore, I favour anti-TNF over UST with deep ileal ulcers.

@ibdseb @TBessissow @novakkerri @DCharabaty @MondayNightIBD @EliLillyandCo @BattatMD4IBD @IBDimmunology @JosephHabibi_MD @BassiMehak @GI_JeffMD @vipuljairath @laura_tee_mdgi @ptandonGI @RPanaccione @marshllj @JeanFredericCo1 @EdwardLoftus2 @SaraElOualiMD @MatthieuAllez @ChrisMa_YYC @NarulaNeeraj @IBD_Afzali @ibdgijami @nloganmd @DrPhil_Gu @ibdtweets @MRegueiroMD @PeyrinBiroulet @RestelliniS @bverstockt @SeverineVermei1 We have a H2H in CD that demonstrated similar efficacy (UST vs ADAL). From a pt perspective, if similar efficacy then most would pick the safer MOA. But agree that there are many factors involved! Experience over innovation doesn’t always apply though (Apple vs Blackberry 😂)

📣Join us now for a convo led by @waqqasafif @DCharabaty Very 🇨🇦: it’s so simple it’s complicated! When most MOAs are a good option what do you recommend for your pt w #Crohns & why? 🗳️Polls 1️⃣Bionaive + 2️⃣Bioexposed 💬Comment below Poll2️⃣ Support by educ grant @EliLillyandCo

@DCharabaty @waqqasafif @MondayNightIBD @EliLillyandCo @BattatMD4IBD @IBDimmunology @JosephHabibi_MD @BassiMehak @vipuljairath @novakkerri @laura_tee_mdgi @ptandonGI @RPanaccione @marshllj @JeanFredericCo1 @EdwardLoftus2 @SaraElOualiMD @MatthieuAllez @ChrisMa_YYC @NarulaNeeraj @IBD_Afzali @ibdgijami @nloganmd @DrPhil_Gu @Bealoquebea @ign76 @Jonathansegal85 @KaazanPatricia @ibdseb @drsumitbhatia @JonnyBlackwell Requires a discussion with patients regarding safety profile and preferred route of administration.

@waqqasafif @MondayNightIBD @EliLillyandCo @BattatMD4IBD @IBDimmunology @JosephHabibi_MD @BassiMehak @GI_JeffMD @vipuljairath @novakkerri @laura_tee_mdgi @ptandonGI @RPanaccione @marshllj @JeanFredericCo1 @EdwardLoftus2 @SaraElOualiMD @MatthieuAllez @ChrisMa_YYC @NarulaNeeraj @IBD_Afzali @ibdgijami @nloganmd @DrPhil_Gu In countries where JAKi are available 1st line option: do you use it in moderate CD? or still prefer Vedo & IL23, & “save” JAKi for more severe Crohns &/or perianal disease &/or EIMs ? @Bealoquebea @ign76 @Jonathansegal85 @KaazanPatricia @ibdseb @drsumitbhatia @JonnyBlackwell ?

Please join us for our post ECCO 2025 IBD Update to review the top presented abstracts. Expert commentary by @vipuljairath Join Here! us02web.zoom.us/webinar/regist…

@marshllj @CanGastroAssn @MacDeptMed @McMasterU @NarulaNeeraj Great job Neeraj!!! @NarulaNeeraj

Congratulations to Dr. Neeraj Narula on his receipt of the 2025 CIHR-INMD-CAG EARLY CAREER RESEARCHER PARTNERSHIP PRIZE! Well deserved and McMaster is proud. @CanGastroAssn @MacDeptMed @McMasterU @NarulaNeeraj

@ibdseb @P_DeepakIBDMD @MayoClinicGIHep @EdwardLoftus2 TOPClass in June!!! Looking forward to it.

@P_DeepakIBDMD @GI_JeffMD @MayoClinicGIHep @EdwardLoftus2 Come and see us

#ECCO2025 fun is also catching up with old friends and current collaborators @GI_JeffMD @MayoClinicGIHep #IBD fellows. Missed you there @EdwardLoftus2 Unfortunately had already drained the beers by the time of the photo!

Looking forward to this!!! Come join us as we review the top practice changing IBD studies of 2024

Dear GI colleagues, HCPs and people living with IBD with perianal fistulas. Please fill out this short survey to help us identify research priorities for perianal Crohn’s disease.

So well deserved!!!! Congrats @DiscoverIBD and for your work in getting CIRC off the ground

Looking forward to this!!! Come join us as we hear from @marshllj and his take on new research in IBD from UEGW!!! PM me if any issues signing up